☰

Robert T. Dorr

Affiliations: 
University of Arizona, Tucson, AZ 
Area:
Pharmaceutical Chemistry, Nutrition, Pharmacology
Google:
"Robert Dorr"
Mean distance: (not calculated yet)
 
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor

Children

Sign in to add trainee
Katerina Dvorakova grad student 2000 University of Arizona
Ross O. Meyers grad student 2005 University of Arizona
Nicholas O. Roman grad student 2005 University of Arizona
Alan A. Pourpak grad student 2006 University of Arizona
Meredith C. Henderson grad student 2008 University of Arizona

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Landowski TH, Guntle GP, Zhao D, et al. (2016) Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. Translational Oncology. 9: 228-35
Samulitis BK, Pond KW, Pond E, et al. (2015) Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biology & Therapy. 16: 43-51
Samulitis Bk, Pond E, Pond K, et al. (2015) Abstract B42: Adaptive drug resistance is associated with phenotypic reprogramming and hypersensitivity to HDAC inhibitors Clinical Cancer Research. 21
Remers WA, Iyengar BS, Dorr RT, et al. (2015) Synthesis and antitumor activity of heterocycles related to carbendazim Journal of Heterocyclic Chemistry. 52: 136-141
Barr PM, Miller TP, Friedberg JW, et al. (2014) Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 124: 1259-65
Landowski TH, Samulitis BK, Dorr RT. (2013) The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancers. Investigational New Drugs. 31: 1616-25
Escalante AM, McGrath RT, Karolak MR, et al. (2013) Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. Cancer Chemotherapy and Pharmacology. 71: 1567-76
Dorr RT, Samulitis BK, Wisner L, et al. (2013) Characterization of a membrane-active anti-tumor agent, UA8967 Investigational New Drugs. 31: 576-586
Barr PM, Briehl MM, Bernstein SH, et al. (2013) Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study Blood. 122: 89-89
Guntle GP, Jagadish B, Mash EA, et al. (2012) Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium. Translational Oncology. 5: 190-9
See more...